Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
In this episode of CURE Talks Cancer, we caught up with all three storytellers from the “Our Way Forward: Stories that Illuminate the Ovarian Cancer Experience,” storytelling event hosted through a special engagement with The Moth.
New research indicates that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) or naproxen (Aleve) could not only reduce the risk of ovarian cancer, but also improve survival with daily use.
After testing positive for the BRCA mutation, Pulaski has become an advocate and authored a book titled “Mom’s Genes,” which focuses on starting the conversation with children about their family’s health history.
Although immunotherapy’s use in ovarian cancer lags other cancer types, Matthew Powell, M.D., believes there is still promise for checkpoint blockades in this field, likely in combination with other agents.